Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2002-04-25

AUTHORS

C-Y Lin, C-H Ho, Y-H Hsieh, T Kikuchi

ABSTRACT

Glycogen storage disease type II (GSD II), Pompe's disease, is caused by the deficiency of acid α-D-glucosidase (GAA) in lysosome and is the most common form of GSD in Taiwan. Most cases are the infantile form. The disease is relentless and most patients die of cardiac failure and respiratory tract infection in the first year of life. At present, no treatment has been proved effective for this fatal disease. The applicability of enzyme replacement therapy is under investigation. However, high price and transient efficiency are the major problems to be solved. Accordingly, gene therapy by viral method has been conducted. In this study we constructed a plasmid that contained 5′-shortened BglII–NotI fragment human GAA cDNA, downstream of CMV promoter and bovine growth hormone polyadenylation signal, as well as AAV ITR region. When fibroblasts obtained from GSD II patients were cultured and infected with rAAV-GAA, the GAA activity of the fibroblasts increased four- to five-fold. Using acid maltase deficient (AMD) Japanese quail as the animal model, rcAAV-GAA 0.1 ml per site (1 × 109-10 particles), totally 10 different sites to make 1 ml (1 × 1010–11 particles), was injected into unilateral deep pectoral muscle of AMD quails. Medium (hepes) was only injected in the same way into the contralateral deep pectoral muscle to serve as control. Four days after injection, PAS staining showed disappearance of the glycogenosomes with regeneration of myocytes surrounding the intramuscular injected area as compared with the contralateral muscle of the same birds. Using anti-GAA monoclonal antibody, GAA was demonstrated on the regenerated myocytes by immunohistochemical staining and absent on the contralateral muscle of the same birds. Nevertheless, T lymphocytes infiltration was noted in both the rcAAV-GAA and hepes (medium) injected muscles and more prominent in the rcAAV-GAA-injected site. Functional evaluation demonstrated that wing flapping movement improved with wide flapping in the rAAV-GAA injected side, but not in the counterpart. Unfortunately, these histochemical and functional improvements faded away in 14 days, probably due to destruction of rcAAV by cell-mediated immunity of infiltrated T cells. Taken together, the present study suggests that rAAV can enter either human or quail cells and express and effectively reduce the glycogen accumulation in the skeletal muscle of AMD quails. These preliminary results are similar to these of low-dose rGAA replacement therapy. The mechanisms underlying the induction of cell-mediated immunity are unknown. How to elevate the number of packaged AAV, enhance the infectivity of AAV and reduce cell-mediated immunity must be solved in the future. More... »

PAGES

554-563

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.gt.3301672

DOI

http://dx.doi.org/10.1038/sj.gt.3301672

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008285111

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11973631


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Coturnix", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dependovirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Vectors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucan 1,4-alpha-Glucosidase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycogen Storage Disease Type II", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intramuscular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Muscle, Skeletal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transduction, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Wings, Animal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "alpha-Glucosidases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan", 
          "id": "http://www.grid.ac/institutes/grid.260770.4", 
          "name": [
            "Department of Pediatrics, Taipei Veterans General Hospital, Taiwan", 
            "Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lin", 
        "givenName": "C-Y", 
        "id": "sg:person.0711051320.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711051320.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan", 
          "id": "http://www.grid.ac/institutes/grid.260770.4", 
          "name": [
            "Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ho", 
        "givenName": "C-H", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan", 
          "id": "http://www.grid.ac/institutes/grid.260770.4", 
          "name": [
            "Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hsieh", 
        "givenName": "Y-H", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Animal Models for Human Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419280.6", 
          "name": [
            "Department of Animal Models for Human Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kikuchi", 
        "givenName": "T", 
        "id": "sg:person.011064726622.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011064726622.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s004010050515", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039452999", 
          "https://doi.org/10.1007/s004010050515"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1203/00006450-199803000-00011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064211572", 
          "https://doi.org/10.1203/00006450-199803000-00011"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2002-04-25", 
    "datePublishedReg": "2002-04-25", 
    "description": "Glycogen storage disease type II (GSD II), Pompe's disease, is caused by the deficiency of acid \u03b1-D-glucosidase (GAA) in lysosome and is the most common form of GSD in Taiwan. Most cases are the infantile form. The disease is relentless and most patients die of cardiac failure and respiratory tract infection in the first year of life. At present, no treatment has been proved effective for this fatal disease. The applicability of enzyme replacement therapy is under investigation. However, high price and transient efficiency are the major problems to be solved. Accordingly, gene therapy by viral method has been conducted. In this study we constructed a plasmid that contained 5\u2032-shortened BglII\u2013NotI fragment human GAA cDNA, downstream of CMV promoter and bovine growth hormone polyadenylation signal, as well as AAV ITR region. When fibroblasts obtained from GSD II patients were cultured and infected with rAAV-GAA, the GAA activity of the fibroblasts increased four- to five-fold. Using acid maltase deficient (AMD) Japanese quail as the animal model, rcAAV-GAA 0.1 ml per site (1 \u00d7 109-10 particles), totally 10 different sites to make 1 ml (1 \u00d7 1010\u201311 particles), was injected into unilateral deep pectoral muscle of AMD quails. Medium (hepes) was only injected in the same way into the contralateral deep pectoral muscle to serve as control. Four days after injection, PAS staining showed disappearance of the glycogenosomes with regeneration of myocytes surrounding the intramuscular injected area as compared with the contralateral muscle of the same birds. Using anti-GAA monoclonal antibody, GAA was demonstrated on the regenerated myocytes by immunohistochemical staining and absent on the contralateral muscle of the same birds. Nevertheless, T lymphocytes infiltration was noted in both the rcAAV-GAA and hepes (medium) injected muscles and more prominent in the rcAAV-GAA-injected site. Functional evaluation demonstrated that wing flapping movement improved with wide flapping in the rAAV-GAA injected side, but not in the counterpart. Unfortunately, these histochemical and functional improvements faded away in 14 days, probably due to destruction of rcAAV by cell-mediated immunity of infiltrated T cells. Taken together, the present study suggests that rAAV can enter either human or quail cells and express and effectively reduce the glycogen accumulation in the skeletal muscle of AMD quails. These preliminary results are similar to these of low-dose rGAA replacement therapy. The mechanisms underlying the induction of cell-mediated immunity are unknown. How to elevate the number of packaged AAV, enhance the infectivity of AAV and reduce cell-mediated immunity must be solved in the future.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.gt.3301672", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1105638", 
        "issn": [
          "0969-7128", 
          "1476-5462"
        ], 
        "name": "Gene Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "cell-mediated immunity", 
      "replacement therapy", 
      "contralateral muscles", 
      "deep pectoral muscles", 
      "regeneration of myocytes", 
      "respiratory tract infections", 
      "enzyme replacement therapy", 
      "glycogen accumulation", 
      "acid maltase deficiency", 
      "GSD II patients", 
      "glycogen storage disease type II", 
      "storage disease type II", 
      "pectoral muscle", 
      "Japanese quail", 
      "regenerated myocytes", 
      "most patients", 
      "tract infections", 
      "lymphocyte infiltration", 
      "cardiac failure", 
      "II patients", 
      "functional improvement", 
      "virus-mediated transfer", 
      "immunohistochemical staining", 
      "Pompe disease", 
      "GAA activity", 
      "animal models", 
      "fatal disease", 
      "maltase deficiency", 
      "transient reduction", 
      "functional evaluation", 
      "PAS staining", 
      "monoclonal antibodies", 
      "disease", 
      "infantile form", 
      "therapy", 
      "skeletal muscle", 
      "muscle", 
      "common form", 
      "immunity", 
      "patients", 
      "bovine growth hormone polyadenylation signal", 
      "same birds", 
      "first year", 
      "gene therapy", 
      "CMV promoter", 
      "myocytes", 
      "present study", 
      "type II", 
      "staining", 
      "acid \u03b1", 
      "quail cells", 
      "AAV", 
      "quail", 
      "deficiency", 
      "days", 
      "most cases", 
      "fibroblasts", 
      "five-fold", 
      "cells", 
      "ITR region", 
      "infection", 
      "antibodies", 
      "infiltration", 
      "injection", 
      "treatment", 
      "glycogenosomes", 
      "infectivity", 
      "study", 
      "adeno", 
      "induction", 
      "accumulation", 
      "rAAV", 
      "major problem", 
      "preliminary results", 
      "failure", 
      "humans", 
      "viral methods", 
      "years", 
      "different sites", 
      "lysosomes", 
      "sites", 
      "Hepes", 
      "destruction", 
      "activity", 
      "control", 
      "cases", 
      "evaluation", 
      "life", 
      "genes", 
      "disappearance", 
      "regeneration", 
      "reduction", 
      "plasmid", 
      "improvement", 
      "Taiwan", 
      "promoter", 
      "mechanism", 
      "birds", 
      "GSD", 
      "cDNA", 
      "same way", 
      "form", 
      "number", 
      "glucosidase", 
      "investigation", 
      "side", 
      "area", 
      "movement", 
      "results", 
      "counterparts", 
      "region", 
      "future", 
      "method", 
      "medium", 
      "model", 
      "polyadenylation signal", 
      "downstream", 
      "signals", 
      "transfer", 
      "transient efficiency", 
      "problem", 
      "way", 
      "maltase genes", 
      "high price", 
      "applicability", 
      "wing", 
      "efficiency", 
      "prices", 
      "GaAs", 
      "disease type II", 
      "BglII\u2013NotI fragment human GAA cDNA", 
      "fragment human GAA cDNA", 
      "human GAA cDNA", 
      "GAA cDNA", 
      "growth hormone polyadenylation signal", 
      "hormone polyadenylation signal", 
      "AAV ITR region", 
      "rAAV-GAA", 
      "acid maltase deficient (AMD) Japanese quail", 
      "maltase deficient (AMD) Japanese quail", 
      "deficient (AMD) Japanese quail", 
      "rcAAV-GAA", 
      "unilateral deep pectoral muscle", 
      "AMD quails", 
      "contralateral deep pectoral muscle", 
      "anti-GAA monoclonal antibody", 
      "destruction of rcAAV", 
      "rcAAV", 
      "low-dose rGAA replacement therapy", 
      "rGAA replacement therapy", 
      "infectivity of AAV", 
      "human acid maltase gene", 
      "acid maltase gene"
    ], 
    "name": "Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency", 
    "pagination": "554-563", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008285111"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.gt.3301672"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11973631"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.gt.3301672", 
      "https://app.dimensions.ai/details/publication/pub.1008285111"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_355.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.gt.3301672"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.gt.3301672'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.gt.3301672'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.gt.3301672'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.gt.3301672'


 

This table displays all metadata directly associated to this object as RDF triples.

310 TRIPLES      22 PREDICATES      197 URIs      187 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.gt.3301672 schema:about N0c67d16250a14f2ba91f4cda6b1ea5f0
2 N0ed7c70ccb834d9784bb5a5100662595
3 N1638d8b8d097466390536a7ffe759529
4 N2b5eb8c7783a4e99abaec21f3b25e3e3
5 N428b56ad22fb4022a4b70b274c67ad12
6 N57cc0017039c43f1ac98432d433d90eb
7 N5cb023c3369e42b6af11c31e24808b5f
8 N6f0c1243731e40148e78c86aadeaa96a
9 N8cc11594d84540a0ab085689a9f7ccf9
10 N92c0f7d778d447e2b35342c4b27cd5c9
11 Na870f25b4d6a42448cf9ede1823140f9
12 Nb69ea8b930a14b228310b2d2b248491c
13 Nc597f5ac2f5c44a5962356343544fab3
14 Nc78c39f2e1f7499db9d381e2e1997412
15 Nc8dd6d318cab4c29afc390c94fa53b07
16 Nd3eb6427017d49f5818645639d595b30
17 anzsrc-for:06
18 anzsrc-for:11
19 schema:author Nd136f97339c84e1fbbb9a3fe5dcf65c5
20 schema:citation sg:pub.10.1007/s004010050515
21 sg:pub.10.1203/00006450-199803000-00011
22 schema:datePublished 2002-04-25
23 schema:datePublishedReg 2002-04-25
24 schema:description Glycogen storage disease type II (GSD II), Pompe's disease, is caused by the deficiency of acid α-D-glucosidase (GAA) in lysosome and is the most common form of GSD in Taiwan. Most cases are the infantile form. The disease is relentless and most patients die of cardiac failure and respiratory tract infection in the first year of life. At present, no treatment has been proved effective for this fatal disease. The applicability of enzyme replacement therapy is under investigation. However, high price and transient efficiency are the major problems to be solved. Accordingly, gene therapy by viral method has been conducted. In this study we constructed a plasmid that contained 5′-shortened BglII–NotI fragment human GAA cDNA, downstream of CMV promoter and bovine growth hormone polyadenylation signal, as well as AAV ITR region. When fibroblasts obtained from GSD II patients were cultured and infected with rAAV-GAA, the GAA activity of the fibroblasts increased four- to five-fold. Using acid maltase deficient (AMD) Japanese quail as the animal model, rcAAV-GAA 0.1 ml per site (1 × 109-10 particles), totally 10 different sites to make 1 ml (1 × 1010–11 particles), was injected into unilateral deep pectoral muscle of AMD quails. Medium (hepes) was only injected in the same way into the contralateral deep pectoral muscle to serve as control. Four days after injection, PAS staining showed disappearance of the glycogenosomes with regeneration of myocytes surrounding the intramuscular injected area as compared with the contralateral muscle of the same birds. Using anti-GAA monoclonal antibody, GAA was demonstrated on the regenerated myocytes by immunohistochemical staining and absent on the contralateral muscle of the same birds. Nevertheless, T lymphocytes infiltration was noted in both the rcAAV-GAA and hepes (medium) injected muscles and more prominent in the rcAAV-GAA-injected site. Functional evaluation demonstrated that wing flapping movement improved with wide flapping in the rAAV-GAA injected side, but not in the counterpart. Unfortunately, these histochemical and functional improvements faded away in 14 days, probably due to destruction of rcAAV by cell-mediated immunity of infiltrated T cells. Taken together, the present study suggests that rAAV can enter either human or quail cells and express and effectively reduce the glycogen accumulation in the skeletal muscle of AMD quails. These preliminary results are similar to these of low-dose rGAA replacement therapy. The mechanisms underlying the induction of cell-mediated immunity are unknown. How to elevate the number of packaged AAV, enhance the infectivity of AAV and reduce cell-mediated immunity must be solved in the future.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N23045d32bf4346179d3d25e194ef34a4
29 N6ce10a30cda04cba8c3e135b0976f694
30 sg:journal.1105638
31 schema:keywords AAV
32 AAV ITR region
33 AMD quails
34 BglII–NotI fragment human GAA cDNA
35 CMV promoter
36 GAA activity
37 GAA cDNA
38 GSD
39 GSD II patients
40 GaAs
41 Hepes
42 II patients
43 ITR region
44 Japanese quail
45 PAS staining
46 Pompe disease
47 Taiwan
48 accumulation
49 acid maltase deficiency
50 acid maltase deficient (AMD) Japanese quail
51 acid maltase gene
52 acid α
53 activity
54 adeno
55 animal models
56 anti-GAA monoclonal antibody
57 antibodies
58 applicability
59 area
60 birds
61 bovine growth hormone polyadenylation signal
62 cDNA
63 cardiac failure
64 cases
65 cell-mediated immunity
66 cells
67 common form
68 contralateral deep pectoral muscle
69 contralateral muscles
70 control
71 counterparts
72 days
73 deep pectoral muscles
74 deficiency
75 deficient (AMD) Japanese quail
76 destruction
77 destruction of rcAAV
78 different sites
79 disappearance
80 disease
81 disease type II
82 downstream
83 efficiency
84 enzyme replacement therapy
85 evaluation
86 failure
87 fatal disease
88 fibroblasts
89 first year
90 five-fold
91 form
92 fragment human GAA cDNA
93 functional evaluation
94 functional improvement
95 future
96 gene therapy
97 genes
98 glucosidase
99 glycogen accumulation
100 glycogen storage disease type II
101 glycogenosomes
102 growth hormone polyadenylation signal
103 high price
104 hormone polyadenylation signal
105 human GAA cDNA
106 human acid maltase gene
107 humans
108 immunity
109 immunohistochemical staining
110 improvement
111 induction
112 infantile form
113 infection
114 infectivity
115 infectivity of AAV
116 infiltration
117 injection
118 investigation
119 life
120 low-dose rGAA replacement therapy
121 lymphocyte infiltration
122 lysosomes
123 major problem
124 maltase deficiency
125 maltase deficient (AMD) Japanese quail
126 maltase genes
127 mechanism
128 medium
129 method
130 model
131 monoclonal antibodies
132 most cases
133 most patients
134 movement
135 muscle
136 myocytes
137 number
138 patients
139 pectoral muscle
140 plasmid
141 polyadenylation signal
142 preliminary results
143 present study
144 prices
145 problem
146 promoter
147 quail
148 quail cells
149 rAAV
150 rAAV-GAA
151 rGAA replacement therapy
152 rcAAV
153 rcAAV-GAA
154 reduction
155 regenerated myocytes
156 regeneration
157 regeneration of myocytes
158 region
159 replacement therapy
160 respiratory tract infections
161 results
162 same birds
163 same way
164 side
165 signals
166 sites
167 skeletal muscle
168 staining
169 storage disease type II
170 study
171 therapy
172 tract infections
173 transfer
174 transient efficiency
175 transient reduction
176 treatment
177 type II
178 unilateral deep pectoral muscle
179 viral methods
180 virus-mediated transfer
181 way
182 wing
183 years
184 schema:name Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency
185 schema:pagination 554-563
186 schema:productId N800522c386c847e3a31c829deb6be334
187 Nac8b2ab42e8241d6b53f337c5f561aa4
188 Ne310388146284b4e83ffc2b5b7909ec2
189 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008285111
190 https://doi.org/10.1038/sj.gt.3301672
191 schema:sdDatePublished 2022-01-01T18:12
192 schema:sdLicense https://scigraph.springernature.com/explorer/license/
193 schema:sdPublisher Ne861fd690afb44559e47b0aa74ddfb4c
194 schema:url https://doi.org/10.1038/sj.gt.3301672
195 sgo:license sg:explorer/license/
196 sgo:sdDataset articles
197 rdf:type schema:ScholarlyArticle
198 N0c67d16250a14f2ba91f4cda6b1ea5f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Muscle, Skeletal
200 rdf:type schema:DefinedTerm
201 N0ed7c70ccb834d9784bb5a5100662595 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Glycogen
203 rdf:type schema:DefinedTerm
204 N1638d8b8d097466390536a7ffe759529 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Glycogen Storage Disease Type II
206 rdf:type schema:DefinedTerm
207 N22bbe3bc0f604ea896b61b0b612fe6bc rdf:first N5acf8040b1914148b92888d0e17d1a64
208 rdf:rest N27c065379f1d4713a4c2bf410419f830
209 N23045d32bf4346179d3d25e194ef34a4 schema:volumeNumber 9
210 rdf:type schema:PublicationVolume
211 N27c065379f1d4713a4c2bf410419f830 rdf:first N62067607dbdd4f0da3d788d078f8d70e
212 rdf:rest N794416b13e92402a918b69ec1717f8cb
213 N2b5eb8c7783a4e99abaec21f3b25e3e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Coturnix
215 rdf:type schema:DefinedTerm
216 N428b56ad22fb4022a4b70b274c67ad12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Wings, Animal
218 rdf:type schema:DefinedTerm
219 N57cc0017039c43f1ac98432d433d90eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Transduction, Genetic
221 rdf:type schema:DefinedTerm
222 N5acf8040b1914148b92888d0e17d1a64 schema:affiliation grid-institutes:grid.260770.4
223 schema:familyName Ho
224 schema:givenName C-H
225 rdf:type schema:Person
226 N5cb023c3369e42b6af11c31e24808b5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
227 schema:name Injections, Intramuscular
228 rdf:type schema:DefinedTerm
229 N62067607dbdd4f0da3d788d078f8d70e schema:affiliation grid-institutes:grid.260770.4
230 schema:familyName Hsieh
231 schema:givenName Y-H
232 rdf:type schema:Person
233 N6ce10a30cda04cba8c3e135b0976f694 schema:issueNumber 9
234 rdf:type schema:PublicationIssue
235 N6f0c1243731e40148e78c86aadeaa96a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
236 schema:name Genetic Therapy
237 rdf:type schema:DefinedTerm
238 N794416b13e92402a918b69ec1717f8cb rdf:first sg:person.011064726622.01
239 rdf:rest rdf:nil
240 N800522c386c847e3a31c829deb6be334 schema:name pubmed_id
241 schema:value 11973631
242 rdf:type schema:PropertyValue
243 N8cc11594d84540a0ab085689a9f7ccf9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
244 schema:name Glucan 1,4-alpha-Glucosidase
245 rdf:type schema:DefinedTerm
246 N92c0f7d778d447e2b35342c4b27cd5c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
247 schema:name alpha-Glucosidases
248 rdf:type schema:DefinedTerm
249 Na870f25b4d6a42448cf9ede1823140f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
250 schema:name Male
251 rdf:type schema:DefinedTerm
252 Nac8b2ab42e8241d6b53f337c5f561aa4 schema:name dimensions_id
253 schema:value pub.1008285111
254 rdf:type schema:PropertyValue
255 Nb69ea8b930a14b228310b2d2b248491c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
256 schema:name Humans
257 rdf:type schema:DefinedTerm
258 Nc597f5ac2f5c44a5962356343544fab3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
259 schema:name Genetic Vectors
260 rdf:type schema:DefinedTerm
261 Nc78c39f2e1f7499db9d381e2e1997412 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
262 schema:name Injections, Intravenous
263 rdf:type schema:DefinedTerm
264 Nc8dd6d318cab4c29afc390c94fa53b07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
265 schema:name Dependovirus
266 rdf:type schema:DefinedTerm
267 Nd136f97339c84e1fbbb9a3fe5dcf65c5 rdf:first sg:person.0711051320.51
268 rdf:rest N22bbe3bc0f604ea896b61b0b612fe6bc
269 Nd3eb6427017d49f5818645639d595b30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
270 schema:name Animals
271 rdf:type schema:DefinedTerm
272 Ne310388146284b4e83ffc2b5b7909ec2 schema:name doi
273 schema:value 10.1038/sj.gt.3301672
274 rdf:type schema:PropertyValue
275 Ne861fd690afb44559e47b0aa74ddfb4c schema:name Springer Nature - SN SciGraph project
276 rdf:type schema:Organization
277 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
278 schema:name Biological Sciences
279 rdf:type schema:DefinedTerm
280 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
281 schema:name Medical and Health Sciences
282 rdf:type schema:DefinedTerm
283 sg:journal.1105638 schema:issn 0969-7128
284 1476-5462
285 schema:name Gene Therapy
286 schema:publisher Springer Nature
287 rdf:type schema:Periodical
288 sg:person.011064726622.01 schema:affiliation grid-institutes:grid.419280.6
289 schema:familyName Kikuchi
290 schema:givenName T
291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011064726622.01
292 rdf:type schema:Person
293 sg:person.0711051320.51 schema:affiliation grid-institutes:grid.260770.4
294 schema:familyName Lin
295 schema:givenName C-Y
296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711051320.51
297 rdf:type schema:Person
298 sg:pub.10.1007/s004010050515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039452999
299 https://doi.org/10.1007/s004010050515
300 rdf:type schema:CreativeWork
301 sg:pub.10.1203/00006450-199803000-00011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064211572
302 https://doi.org/10.1203/00006450-199803000-00011
303 rdf:type schema:CreativeWork
304 grid-institutes:grid.260770.4 schema:alternateName Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan
305 schema:name Department of Pediatrics, Taipei Veterans General Hospital, Taiwan
306 Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan
307 rdf:type schema:Organization
308 grid-institutes:grid.419280.6 schema:alternateName Department of Animal Models for Human Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan
309 schema:name Department of Animal Models for Human Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan
310 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...